Metastatic progression can be conceptualized as a series of biological events beginning with local invasion. Here, cancer cells undergo genetic and epigenetic alterations that enable them to breach the basement membrane and infiltrate adjacent stromal tissues. This invasiveness is often facilitated by epithelial-mesenchymal transition (EMT), a phenotypic shift allowing tumor cells to acquire motility and resist anoikis—programmed cell death triggered by detachment from extracellular matrices. EMT’s role extends beyond mere motility, as it also modulates stemness and immune evasion properties, making migrating tumor cells especially resilient to therapeutic assaults.

Following local invasion, the intravasation phase introduces circulating tumor cells (CTCs) into the bloodstream or lymphatic vessels. This step is fraught with peril for cancer cells because of biomechanical shear forces and immune surveillance mechanisms. However, tumor cells subvert these challenges by forming clusters, often associating with platelets to shield themselves from immune detection. The dynamic interplay between CTCs and the immune system is an active area of research, revealing potential targets such as immune checkpoints and adhesion molecules which could be manipulated to disrupt metastatic dissemination.

Circulating tumor cells eventually arrest in capillary beds of distant organs—a phase known as extravasation—where they exit the vasculature to invade new tissue microenvironments. This step is not random; metastatic colonization exhibits organotropism, where specific cancers favor particular metastasis sites, such as breast cancer to bone or lungs. The “seed and soil” hypothesis, originally proposed over a century ago, is now supported by molecular evidence showing how tumor cells adapt to or condition distant niches via secreted exosomes and cytokines, preparing the soil for incoming seeds and enhancing metastatic colonization.

The complexity of the metastatic microenvironment constitutes a major hurdle for therapy. Once seeded, metastatic cells enter a dormant state that can last months or years, evading detection and resisting cytotoxic drugs that typically target dividing cells. Awakening dormant cells from this quiescent phase or eradicating them before this phase begins is a therapeutic challenge that remains unresolved. Dormancy is regulated by intricate signaling from both cancer cells and their microenvironment, highlighting the necessity of designing therapies that disrupt these dormant niches.

Traditional therapeutic approaches—surgery, radiation, and systemic chemotherapy—address primary tumors effectively but often fail against metastasis. The mechanisms that endow metastatic cells with resistance include altered drug transport, activation of survival pathways, and phenotypic plasticity. Chemoresistance is further compounded by tumor heterogeneity, an inherent feature of metastatic lesions, where genetically diverse clones coexist. This heterogeneity fuels adaptive resistance, rendering many therapies transiently effective or ineffective altogether.

Innovations in targeted therapies have shown promise by exploiting specific mutations or signaling aberrations within metastatic cells, yet they often encounter eventual resistance. For example, inhibitors of the PI3K/AKT/mTOR pathway, frequently dysregulated in advanced cancers, initially suppress tumor growth but often lead to compensatory feedback loops restoring malignancy. The adaptive complexity underscores the need for combinatorial regimens and precision medicine approaches that tailor treatment to individual tumor profiles.

Immunotherapy has revolutionized oncology, yet its impact on metastatic disease is paradoxical. While checkpoint inhibitors unleash the immune system against tumors, metastatic lesions frequently evolve immune-suppressive microenvironments, characterized by regulatory T cells, myeloid-derived suppressor cells, and immune checkpoint molecule expression. These immunosuppressive barriers limit immunotherapy efficacy, prompting research into strategies that reprogram the microenvironment or combine immunotherapy with other modalities to overcome resistance.

Another burgeoning avenue involves targeting the metastatic niche itself. Understanding how stromal cells, extracellular matrix components, and resident immune cells contribute to metastatic growth offers novel intervention points. Agents disrupting the supportive interactions between cancer cells and their niche could effectively starve metastases or convert their microenvironment from tumor-promoting to tumor-suppressing.

Technological advances in single-cell sequencing and liquid biopsies facilitate real-time monitoring of metastatic dynamics, allowing clinicians to track tumor evolution and therapeutic responsiveness. This dynamic approach enables adaptive treatment modifications, identifying minimal residual disease before clinical relapse and ushering in a new paradigm of proactive metastasis management rather than reactive care.

Nanomedicine developments also present exciting prospects. Nanoparticles engineered to deliver drugs specifically to metastatic cells, or to modulate the microenvironment, minimize systemic toxicity and improve therapeutic indices. Multifunctional nanoparticles designed to release payloads in response to tumor-specific stimuli enhance precision and overcome traditional drug delivery challenges.

Despite these advances, challenges persist regarding drug delivery across biological barriers in metastatic sites such as the brain or bone marrow. The blood-brain barrier, for example, restricts many chemotherapeutics and biologics, necessitating innovative delivery methods such as focused ultrasound or receptor-mediated transcytosis to breach these formidable defenses.

Collectively, these insights emphasize a multifaceted therapeutic approach, integrating molecular targeting, immune modulation, microenvironmental remodeling, and advanced drug delivery technologies. The future of metastasis therapy lies in leveraging these convergent strategies to prevent dissemination, eradicate micrometastases, and prevent recurrence, thereby improving long-term patient survival and quality of life.

In conclusion, metastasis represents a biological enigma and a clinical conundrum with far-reaching implications for cancer prognosis and treatment. While current therapies fall short of curing metastatic disease, burgeoning research illuminated by studies such as that of Garemilla and colleagues offers unprecedented clarity on underlying mechanisms and therapeutic vulnerabilities. By embracing the complexity rather than oversimplifying metastatic biology, the oncology community is poised to transform cancer treatment, shifting from palliative intent to curative potential even in the face of the most aggressive cancer spread.

Subject of Research: Cancer metastasis and its therapeutic challenges and opportunities

Article Title: Cancer Metastasis: Therapeutic Challenges and Opportunities

Article References:

Garemilla, S.S.S., Kadambala, M.C., Gampa, S.C. et al. Cancer Metastasis: Therapeutic Challenges and Opportunities.
Med Oncol 42, 518 (2025). https://doi.org/10.1007/s12032-025-03072-x

Image Credits: AI Generated

Scientists have long speculated that the physical microenvironment encountered by cancer cells in circulation plays a crucial role in their ability to colonize new tissues. This new study elucidates how the extreme mechanical stresses imposed by the confines of tiny capillaries can induce profound changes in cancer cell behavior. Specifically, researchers recreated the restrictive forces cancer cells endure during circulation using an innovative microfluidic device designed to mimic the human microvascular network. This allowed precise observation of how human melanoma cells react to being forced through channels narrower than 10 micrometres—roughly one-fifth the diameter of a human hair.

Through this bioengineered platform, constructed from biocompatible PDMS (polydimethylsiloxane), cancer cells were subjected to deformation comparable to physiological capillary constrictions. The exposure to these mechanical constraints triggered cancer cells to adopt stem cell-like phenotypes, a state believed to be more tumorigenic and highly capable of survival under hostile conditions. Proteomic analysis revealed upregulation of proteins associated with metastasis and cellular plasticity, demonstrating that mechanical forces alone can prime cancer cells for enhanced malignancy.

The significance of this transformation was underscored through in vivo experiments. When these mechanically “squeezed” melanoma cells were injected into immunodeficient mice, the animals developed significantly more secondary tumours in critical organs such as the lungs, bones, and brain, compared to mice injected with unsqueezed cells. These findings imply that physical deformation encountered during vascular transit acts as a key driver in metastasis progression, essentially reprogramming cancer cells into a more aggressive phenotype capable of colonizing distant tissues.

This discovery challenges the traditional view that metastasis is solely dependent on rare populations of pre-existing cancer stem cells. Instead, it suggests that the biomechanical landscape—specifically the constrictive forces within capillaries—can dynamically induce tumorigenic capabilities in otherwise less aggressive circulating tumour cells. This could revolutionize our understanding of cancer dissemination, shifting some focus from purely genetic and biochemical factors to include physical influences in the metastatic cascade.

The microfluidic model developed by Dr. Giulia Silvani and her team allowed for the real-time simulation of blood plasma flow at physiological rates through channels whose widths progressively narrowed from 30 micrometres down to just 5 micrometres. This high-resolution platform provided a rare window into the mechanical stress responses of cancer cells during their circulation journey. Given the difficulty in tracking these cells in vivo, this approach represents a significant technological advance in metastasis research.

Through detailed cellular and molecular analyses, the researchers uncovered a critical role for mechanosensitive ion channels such as PIEZO1 in mediating this phenotypic shift. PIEZO1 acts as a cellular sensor, translating mechanical forces into biochemical signals that activate cancer cell reprogramming. Targeting such mechanotransduction pathways could open new therapeutic avenues to prevent or diminish metastatic outgrowth by disrupting the mechanical cues essential for cancer cell transformation.

Importantly, melanoma was chosen as a model due to its well-known aggressive metastatic behavior and high mortality rates once it disseminates beyond the skin. However, the team is optimistic that similar squeezing-induced plasticity will be observed in other cancers, such as breast cancer, which may similarly exploit capillary constriction to enhance metastatic potential. This broad applicability could herald a paradigm shift in how cancer metastasis mechanisms are studied and targeted.

The implications for clinical practice and diagnosis are compelling. Researchers envisage a future where patient blood samples are analyzed not just for circulating tumor cell counts, but for cellular susceptibility to mechanical transformation. This might provide a personalized metastasis risk assessment. Additionally, imaging techniques like MRI could identify microvascular “hotspots” where constrictions favor cell squeezing, allowing targeted prevention strategies.

This research underscores the vital intersection of engineering, biology, and medicine. By integrating microfabrication technology with cellular biology, scientists have illuminated a mechanical trigger previously obscured in cancer metastasis. This multi-disciplinary approach promises to refine therapeutic strategies, combining traditional molecular targeting with mechanical interventions that impede cancer cell priming.

As the fight against metastasis continues, unraveling the mechanical microenvironments and their influence on cancer progression emerges as a promising frontier. The UNSW Sydney team’s findings advance this field, providing not only a mechanistic explanation for increased tumorigenicity but also a roadmap for novel diagnostic and therapeutic innovations aimed at preventing the deadly spread of cancer.

—

Subject of Research: Cells

Article Title: Capillary constrictions prime cancer cell tumorigenicity through PIEZO1

News Publication Date: 1-Sep-2025

Web References:
https://www.nature.com/articles/s41467-025-63374-6

References:
DOI: 10.1038/s41467-025-63374-6

Keywords: Metastasis, Cancer, Skin cancer, Blood vessels, Microfluidics